MBX Biosciences
MBX
54.54
-2.38
-4.18%
MBX Biosciences
US · MBX
#2567 by market cap
Listed 2024
54.54
-2.38
-4.18%
Live - 5344 symbols - heartbeat 36s ago
· 2026-10-07 23:20
After-hours
54.32
-0.40%
Overnight
55.19
+1.19%
- Market cap
- 2.63B
- P/E (TTM)i
- -23.01
- P/Bi
- 6.41
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on MBX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 2.0 percentage points.
Institutional ownership
- Held by institutions
- 115.55% -1.95pp
- Institutions
- 205
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund54.54%
VC/PE Fund37.09%
Hedge Fund21.02%
Individual/Insider2.74%
Public Company2.24%
Government Pension Fund0.24%
Insurance Company0.19%
Private Company0.17%
Top holders as of 2026-08-06
Frazier Life Sciences Management, LP
13.81% · 6.65M sh
FMR
11.05% · 5.32M sh
Wellington Management Group
10.34% · 4.98M sh
New Enterprise Associates, Inc.
7.51% · 3.61M sh
BlackRock
6.90% · 3.32M sh
OrbiMed Advisors LLC
6.38% · 3.07M sh
Paradigm Biocapital Advisors LP
5.21% · 2.51M sh
NVP Associates, LLC
4.44% · 2.14M sh
Deep Track Capital, LP
3.60% · 1.73M sh
Vanguard Capital Management, LLC
3.49% · 1.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 13.81% |
| Wellington Management Group | -- | 10.34% |
| Peter Hawryluk | Chief Executive Officer | 2.52% |
| Richard Bartram | Chief Financial Officer | 0.10% |
| Ora Pescovitz | Independent Director | 0.05% |
| Steven Hoerter | Independent Director | 0.04% |
| Salomon Azoulay | Chief Medical Officer | 0.03% |
| Patrick Heron | Independent Director | -- |
| OrbiMed Advisors LLC | -- | -- |
| James Cornelius | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-16 | Peter Hawryluk | Chief Executive Officer | Intent to Sell (Form 144) | -3,745 | $68.29 |
| 2026-08-03 | Peter Hawryluk | Chief Executive Officer | Intent to Sell (Form 144) | -936 | $65.77 |
| 2026-08-03 | Salomon Azoulay | Chief Medical Officer | Open Market Disposition | -370 | $65.77 |
| 2026-08-02 | John Smither | Interim Chief Financial Officer | Other Acquisition | +28,000 | -- |
| 2026-08-02 | John Smither | Interim Chief Financial Officer | Other Derivative Acquisition | +130,000 | $64.41 |
| 2026-08-02 | Steven Hoerter | Independent Director | Other Acquisition | +71,000 | -- |
| 2026-08-02 | Steven Hoerter | Independent Director | Other Derivative Acquisition | +331,000 | $64.41 |
| 2026-06-09 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -9,167 | $30.55 |
| 2026-06-08 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -10,833 | $29.66 |
| 2026-06-03 | Patrick Heron | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Edward Mathers | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Ora Pescovitz | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Tiba Aynechi | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Steven Ryder | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Steven Hoerter | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-06-03 | Laurie Stelzer | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 |
| 2026-05-12 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -15,000 | $36.95 |
| 2026-05-10 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -22,500 | $44.08 |
| 2026-05-07 | Richard Bartram | Chief Financial Officer | Intent to Sell (Form 144) | -10,000 | $37.96 |
| 2026-05-07 | Salomon Azoulay | Chief Medical Officer | Derivative Exercise and Sale | -70,003 | $10.46–38.38 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 23:20:28 · For reference only, not investment advice and not tailored to your situation.